Other Targets
- Under the terms of the Schrödinger partnership, Nimbus has exclusive access to an evergreen list of 20 targets.
- This allows Nimbus to retain a continuous lock on the most valuable targets in inflammation, anti-infectives, cardiovascular disease, fibrosis, oncology including cancer metabolism, neuropathic pain, COPD and other lung diseases, and Parkinson’s.